ClearPoint Neuro (CLPT) Return on Capital Employed (2012 - 2026)
ClearPoint Neuro (CLPT) reported Return on Capital Employed of 30.75% for Q1 2026, up 4734.0% on a YoY basis from 0.64% in Q1 2025, and up 13.09% sequentially from 35.39% in Q4 2025.
ClearPoint Neuro (CLPT) Return on Capital Employed (2012 - 2026) Analysis & Trends
ClearPoint Neuro (CLPT) has 14 years of Return on Capital Employed data on file, last reported at 30.75% in Q1 2026.
- For the quarter ending Q1 2026, Return on Capital Employed rose 4734.0% year-over-year to 30.75%; the trailing twelve-month figure through Mar 2026 stood at 30.75% (up 4734.0% YoY), and the FY2025 full-year result was 41.88%, up 2267.0% from the prior year.
- Return on Capital Employed grew to 30.75% in Q1 2026, from 35.39% in the prior quarter.
- In the past five years, Return on Capital Employed ranged from a high of 25.22% in Q1 2022 to a low of 78.09% in Q1 2025.
- A 5-year average of 46.91% and a median of 48.43% in 2024 frame the typical range for Return on Capital Employed.
- Across the five-year window, Return on Capital Employed tumbled 2989 bps in 2023 and soared 4734 bps in 2026, its largest moves.
- Tracing CLPT's Return on Capital Employed over 5 years: stood at 32.78% in 2022, then tumbled by 91 bps to 62.67% in 2023, then dropped by 7 bps to 67.26% in 2024, then surged by 47 bps to 35.39% in 2025, then rose by 13 bps to 30.75% in 2026.
- Business Quant data shows CLPT's Return on Capital Employed at 30.75% in Q1 2026, 35.39% in Q4 2025, and 42.49% in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | ROCE (Qtr) |
|---|---|---|---|---|---|
| 1 | Abbott Laboratories | 201.40 Bn | 194.75 Bn | 6.27 Bn | 9.61% |
| 2 | Stryker | 122.29 Bn | 119.41 Bn | 3.81 Bn | 12.24% |
| 3 | Medtronic | 105.01 Bn | 96.40 Bn | 6.41 Bn | 8.02% |
| 4 | Boston Scientific | 64.81 Bn | 63.59 Bn | 3.61 Bn | 9.62% |
| 5 | Edwards Lifesciences | 55.28 Bn | 51.60 Bn | 1.29 Bn | 11.13% |
| 6 | Dexcom | 29.06 Bn | 27.94 Bn | 750.30 Mn | 24.24% |
| 7 | Koninklijke Philips | 29.02 Bn | 25.93 Bn | 2.07 Bn | 8.38% |
| 8 | GE HealthCare Technologies | 28.27 Bn | 26.20 Bn | 1.98 Bn | 9.30% |
| 9 | Smith & Nephew | 25.80 Bn | 25.22 Bn | - | - |
| 10 | ClearPoint Neuro | 434.51 Mn | 398.91 Mn | 7.76 Mn | -30.75% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -30.75% |
| Dec 31, 2025 | -35.39% |
| Sep 30, 2025 | -42.49% |
| Jun 30, 2025 | -57.94% |
| Mar 31, 2025 | -78.09% |
| Dec 31, 2024 | -67.26% |
| Sep 30, 2024 | -48.43% |
| Jun 30, 2024 | -50.93% |
| Mar 31, 2024 | -63.50% |
| Dec 31, 2023 | -62.67% |
| Sep 30, 2023 | -55.32% |
| Jun 30, 2023 | -49.38% |
| Mar 31, 2023 | -38.83% |
| Dec 31, 2022 | -32.78% |
| Sep 30, 2022 | -29.96% |
| Jun 30, 2022 | -28.55% |
| Mar 31, 2022 | -25.22% |
| Dec 31, 2021 | -21.44% |
| Sep 30, 2021 | -17.68% |
| Jun 30, 2021 | -13.24% |